Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.
Immunotherapy is a promising approach in the treatment of cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit. Immunotherapy